PROFESSIONAL EDITION

The largest community of pharma leaders

Editor´s Pick

Merck to Discontinue Development of MK-7110 for COVID-19

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the discontinuation of development of MK-7110 (formerly known...

Who’s Getting Vaccinated in the US?

BELLEVUE, Wash.--(BUSINESS WIRE)--New data from USAFacts paints a portrait of who is getting vaccinated for COVID-19 in the US — a portrait that’s uneven,...

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

OXFORD, England--(BUSINESS WIRE)--Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The...

$13M Payday for Moderna CEO Shows Cause to Abandon Vaccine Patents, Says AHF

WASHINGTON--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) today is citing the recent $13 million payday announced for Moderna CEO Stéphane Bancel as just cause for a...

Recent Articles